Get the Stockscreener App
2.42
4.72%
-0.12
After Hours:
2.46
0.04
+1.65%
Eledon Pharmaceuticals Inc stock is traded at $2.42, with a volume of 677.47K.
It is down -4.72% in the last 24 hours and down -9.02% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$2.54
Open:
$2.52
24h Volume:
677.47K
Relative Volume:
0.88
Market Cap:
$144.91M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-1.352
EPS:
-1.79
Net Cash Flow:
$-39.53M
1W Performance:
-10.70%
1M Performance:
-9.02%
6M Performance:
-35.47%
1Y Performance:
-3.97%
1-Day Range:
$2.41
$2.545
1-Week Range:
$2.41
$2.8002
52-Week Range:
$2.375
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.42 | 155.09M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Is a relief rally coming for Eledon Pharmaceuticals Inc. holdersJuly 2025 EndofMonth & Real-Time Volume Triggers - Newser
Published on: 2025-09-12 19:35:20 - Newser
why eledon pharmaceuticals inc. is moving todayJuly 2025 Selloffs & Short-Term High Return Strategies - Newser
Institutional scanner results for Eledon Pharmaceuticals Inc.July 2025 Opening Moves & Risk Controlled Swing Trade Alerts - Newser
Relative strength of Eledon Pharmaceuticals Inc. in sector analysisQuarterly Portfolio Summary & Growth Oriented Trading Recommendations - Newser
Eledon Pharmaceuticals Inc. stock volume spike explainedWeekly Trade Review & Smart Investment Allocation Tips - Newser
How sentiment analysis helps forecast Eledon Pharmaceuticals Inc.July 2025 Review & Weekly High Potential Stock Alerts - Newser
Is Eledon Pharmaceuticals Inc. stock bottoming out2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - Newser
Leading vs lagging indicators on Eledon Pharmaceuticals Inc. performanceJuly 2025 Momentum & Short-Term High Return Strategies - Newser
Heatmap analysis for Eledon Pharmaceuticals Inc. and competitors2025 Retail Activity & Free Real-Time Market Sentiment Alerts - Newser
Sector ETF performance correlation with Eledon Pharmaceuticals Inc.2025 Volatility Report & Safe Capital Preservation Plans - Newser
Has Eledon Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewEarnings Risk Summary & Expert Curated Trade Ideas - Newser
Technical analysis overview for Eledon Pharmaceuticals Inc. stockBuy Signal & Expert Approved Momentum Trade Ideas - Newser
Backtesting results for Eledon Pharmaceuticals Inc. trading strategies2025 Year in Review & Free Expert Verified Stock Movement Alerts - Newser
Tools to monitor Eledon Pharmaceuticals Inc. recovery probabilityTrade Performance Summary & AI Driven Stock Reports - Newser
How to read the order book for Eledon Pharmaceuticals Inc.Quarterly Earnings Summary & Fast Gain Stock Trading Tips - Newser
Using fundamentals and technicals on Eledon Pharmaceuticals Inc.2025 Market Outlook & AI Forecast Swing Trade Picks - Newser
What the charts say about Eledon Pharmaceuticals Inc. todayExit Point & Verified Short-Term Trading Plans - Newser
Pattern recognition hints at Eledon Pharmaceuticals Inc. upsideBuy Signal & Stock Portfolio Risk Management - Newser
Exome Asset Management LLC Has $387,000 Stake in Eledon Pharmaceuticals, Inc. $ELDN - MarketBeat
Eledon Pharmaceuticals Inc. stock trend forecastRecession Risk & Low Drawdown Investment Ideas - Newser
Why Eledon Pharmaceuticals Inc. is moving todayEarnings Summary Report & High Accuracy Trade Signal Alerts - Newser
Will Eledon Pharmaceuticals Inc. outperform the marketMarket Weekly Review & Weekly High Return Forecasts - Newser
What indicators show strength in Eledon Pharmaceuticals Inc.Market Trend Report & Reliable Intraday Trade Plans - Newser
Eledon Pharmaceuticals Inc. stock trendline breakdownJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - Newser
Key resistance and support levels for Eledon Pharmaceuticals Inc.2025 Sector Review & Safe Entry Zone Tips - Newser
Published on: 2025-09-10 06:13:35 - Newser
Understanding Eledon Pharmaceuticals Inc.’s price movement2025 Dividend Review & Risk Managed Investment Strategies - Newser
How high can Eledon Pharmaceuticals Inc. stock goJuly 2025 Short Interest & AI Powered Market Entry Ideas - Newser
Is Eledon Pharmaceuticals Inc. forming a reversal pattern2025 AllTime Highs & High Accuracy Swing Trade Signals - Newser
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):